NO20024255D0 - HIV-immun adjuvansterapi - Google Patents

HIV-immun adjuvansterapi

Info

Publication number
NO20024255D0
NO20024255D0 NO20024255A NO20024255A NO20024255D0 NO 20024255 D0 NO20024255 D0 NO 20024255D0 NO 20024255 A NO20024255 A NO 20024255A NO 20024255 A NO20024255 A NO 20024255A NO 20024255 D0 NO20024255 D0 NO 20024255D0
Authority
NO
Norway
Prior art keywords
adjuvant therapy
immune adjuvant
hiv immune
hiv
therapy
Prior art date
Application number
NO20024255A
Other languages
English (en)
Other versions
NO20024255L (no
Inventor
Mark A Laughlin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20024255D0 publication Critical patent/NO20024255D0/no
Publication of NO20024255L publication Critical patent/NO20024255L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20024255A 2000-03-09 2002-09-06 HIV-immun adjuvansterapi NO20024255L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18833800P 2000-03-09 2000-03-09
PCT/US2001/007453 WO2001066132A2 (en) 2000-03-09 2001-03-08 Hiv immune adjuvant therapy

Publications (2)

Publication Number Publication Date
NO20024255D0 true NO20024255D0 (no) 2002-09-06
NO20024255L NO20024255L (no) 2002-09-06

Family

ID=22692745

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024255A NO20024255L (no) 2000-03-09 2002-09-06 HIV-immun adjuvansterapi

Country Status (14)

Country Link
US (1) US20020004584A1 (no)
EP (1) EP1263457A2 (no)
JP (1) JP2003525907A (no)
CN (1) CN1416351A (no)
AU (1) AU2001249120A1 (no)
BR (1) BR0108997A (no)
CA (1) CA2402024A1 (no)
HK (1) HK1047406A1 (no)
HU (1) HUP0300354A3 (no)
MX (1) MXPA02008756A (no)
NO (1) NO20024255L (no)
NZ (1) NZ520055A (no)
WO (1) WO2001066132A2 (no)
ZA (1) ZA200205846B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849372B2 (en) 2012-09-28 2017-12-26 Sony Interactive Entertainment Inc. Method and apparatus for improving efficiency without increasing latency in emulation of a legacy application title
CN1944644B (zh) * 2006-06-20 2011-11-16 浙江大学 HIV-1gp120与人γ干扰素融合蛋白的制备方法
CN103153311A (zh) 2010-06-03 2013-06-12 药品循环公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
US9694276B2 (en) 2012-06-29 2017-07-04 Sony Interactive Entertainment Inc. Pre-loading translated code in cloud based emulated applications
US9925468B2 (en) 2012-06-29 2018-03-27 Sony Interactive Entertainment Inc. Suspending state of cloud-based legacy applications
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US10406429B2 (en) 2012-08-29 2019-09-10 Sony Interactive Entertainment, LLC User-based mini-game generation and distribution
US9707476B2 (en) 2012-09-28 2017-07-18 Sony Interactive Entertainment Inc. Method for creating a mini-game
US11013993B2 (en) 2012-09-28 2021-05-25 Sony Interactive Entertainment Inc. Pre-loading translated code in cloud based emulated applications
JP2015536950A (ja) 2012-11-02 2015-12-24 ファーマサイクリックス，インク． Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
MX9307733A (es) * 1992-12-23 1994-06-30 Schering Corp Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo.
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
NZ276943A (en) * 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
CO5160259A1 (es) * 1999-03-02 2002-05-30 Schering Corp Interferon alfa pegilado en la terapia contra el hiv
US20020182179A1 (en) * 1999-03-02 2002-12-05 Laughlin Mark A HIV Therapy

Also Published As

Publication number Publication date
JP2003525907A (ja) 2003-09-02
ZA200205846B (en) 2003-10-22
US20020004584A1 (en) 2002-01-10
AU2001249120A1 (en) 2001-09-17
WO2001066132A3 (en) 2002-01-24
NZ520055A (en) 2004-06-25
CN1416351A (zh) 2003-05-07
WO2001066132A2 (en) 2001-09-13
HK1047406A1 (zh) 2003-02-21
EP1263457A2 (en) 2002-12-11
NO20024255L (no) 2002-09-06
MXPA02008756A (es) 2003-02-24
HUP0300354A2 (hu) 2003-06-28
HUP0300354A3 (en) 2005-07-28
BR0108997A (pt) 2003-06-03
CA2402024A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
NO20031483D0 (no) Vaksine
NO20024172D0 (no) Vaksine
NO20014323D0 (no) Vaksine
DK1265633T3 (da) Vaccineadjuvans
DK1326638T3 (da) Vacciner mod cancer
DK1427444T3 (da) West-nil-vaccine
DK1139764T3 (da) Adjuvanssammensætning
GB0130215D0 (en) Vaccine
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20033882L (no) Vaksine
NO20020763L (no) Vaksine
GB0121171D0 (en) Vaccine
NO20024255D0 (no) HIV-immun adjuvansterapi
DE60009451D1 (de) Massagegerät
DE60125927D1 (de) Impfstoffe gegen hiv
DE10290185D2 (de) Tumorvakzine
NO20032086D0 (no) Adjuvant kombinasjonsformuleringer
DK1105498T3 (da) HIV vaccine
FI20002308A (fi) Saunan kiuas
DE10157913B4 (de) Therapietisch
NO20012126D0 (no) HIV-vaksine
ITMI992410A0 (it) Vaccino per hiv
FR2803326B3 (fr) Coffre-fort
NO20011990D0 (no) Kreftvaksine
ITMI981384A0 (it) Vaccino per hiv

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application